<10           : 1.6 g every 12 hours
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                : Not dialysed. Dose as in GFR <10 mL/min
HD                     : Dialysed. Dose as in GFR <10 mL/min
HDF/high flux   : Dialysed. Dose as in GFR <10 mL/min
CAV/VVHD      : Unknown dialysability. Dose as in GFR=10–30 mL/min or 2.4 g every 6–8 hours1 CVVhd/ HDF Dialysed. 3.2 g every 6 hours1
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Anticoagulants: effects of coumarins are potentially enhanced Oral contraceptives: potentially reduced efficacy Methotrexate: reduced excretion thereby increasing risk of toxicity
ADMINISTRATION
Reconstition
With 10 mL water for injection and add to 100 mL glucose 5%
Route
IV
Rate of Administration
30–40 minutes
Comments
Each 3.2 g of ticarcillin/clavulanic acid contains 16 mmol of sodium and 1 mmol of potassium
OTHER INFORMATION
CSM has advised that cholestatic jaundice may occur if treatment exceeds a period of 14 days and can present up to 6 weeks after treatment has been stopped. The incidence of cholestatic jaundice occurring with Timentin is higher in males than in females and is particularly prevalent in men over the age of 65 years